NASDAQ: INABIn8bio Inc Stock
$3.15+0.09 (+2.94%)
Updated Jun 2, 2023
In8bio shares are trading lower... find out Why INAB Price Moved with a free WallStreetZen account
Why Price MovedINAB Price
$3.15
Fair Value Price
N/A
Market Cap
$93.71M
52 Week Low
$1.02
52 Week High
$3.95
P/E
-2.37x
P/B
5.58x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$29.90M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.47
Operating Cash Flow
-$27M
Beta
1.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
INAB Overview
IN8bio Incorporated is a biotech company developing gamma-delta T cell therapies for the treatment of cancers. Its pipeline includes INB-200, a genetically modified autologous gamma-delta T cell candidate in Phase I clinical trials for the treatment of glioblastoma and solid tumors, and INB-100, an allogeneic product candidate, in Phase I clinical trials to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. IN8bio was incorporated in 2016 and is headquartered in New York, NY.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INAB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INAB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
INAB is poor value based on its book value relative to its share price (5.58x), compared to the US Biotechnology industry average (5.2x)
P/B vs Industry Valuation
INAB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more INAB due diligence checks available for Premium users.
Be the first to know about important INAB news, forecast changes, insider trades & much more!
INAB News
Valuation
INAB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.37x
Industry
11.51x
Market
52.69x
INAB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.58x
Industry
5.2x
INAB is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INAB's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.5M
Profit Margin
0%
INAB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$24.7M
Liabilities
$7.9M
Debt to equity
0.47
INAB's short-term assets ($14.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INAB's short-term assets ($14.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INAB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.4M
Investing
-$429.0k
Financing
$547.0k
INAB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INAB vs Biotech Stocks
In8bio Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.